Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy? (Q40867107)

24 September 2017

1 reference

title

Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy? (English)

1 reference

24 September 2017

Gibaldi M

1

1 reference

PubMed ID

9506003

24 September 2017

language of work or name

1 reference

1 December 1997

1 reference

The Journal of Clinical Pharmacology

24 September 2017

1 reference

24 September 2017

37

1 reference

24 September 2017

12

1 reference

24 September 2017

1087-1099

1 reference

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

24 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Osteoporosis in men: epidemiology, pathophysiology, and treatment possibilities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Treatment of postmenopausal osteoporosis with transdermal estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Hormone replacement therapy and cardiovascular risk: the cardiovascular physicians' viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

A prospective study of postmenopausal estrogen therapy and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Hormone therapy to prevent disease and prolong life in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Estrogen stakes claim to cognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Estrogen deficiency and risk of Alzheimer's disease in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Smoking and oestrogen-replacement therapy as protective factors for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Estrogen replacement therapy and cognitive function in older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Postmenopausal hormone therapy and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Hormone replacement therapy and risk of venous thromboembolism: population based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Controversies surrounding estrogen use in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Therapy of osteoporosis: calcium, vitamin D, and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Prevention and management of osteoporosis. Current trends and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

The osteoporosis revolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Studies of the oral bioavailability of alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Esophagitis associated with the use of alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Patient-specific decisions about hormone replacement therapy in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

ER beta: identification and characterization of a novel human estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Prospective study of exogenous hormones and risk of pulmonary embolism in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

Attitudes of women toward hormone therapy and prevention of heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04292.X

10.1002/J.1552-4604.1997.TB04292.X

21 January 2018

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9506003